Body composition and lung cancer-associated cachexia in TRACERx.
Saved in:
| Title: | Body composition and lung cancer-associated cachexia in TRACERx. |
|---|---|
| Authors: | Al-Sawaf O; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Weiss J; Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Diagnostic and Interventional Radiology, University Freiburg, Freiburg, Germany., Skrzypski M; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland., Lam JM; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Department of Oncology, University College London Hospitals, London, UK., Karasaki T; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Zambrana F; Infanta Sofía University Hospital, Madrid, Spain., Kidd AC; Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK., Frankell AM; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Watkins TBK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Martínez-Ruiz C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Puttick C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Black JRM; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Huebner A; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Bakir MA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Sokač M; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.; Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark., Collins S; Early Clinical Development, Pfizer UK Ltd, Cambridge, UK., Veeriah S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Magno N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Naceur-Lombardelli C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Prymas P; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Toncheva A; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Ward S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Advanced Sequencing Facility, The Francis Crick Institute, London, UK., Jayanth N; Cancer Research UK & UCL Cancer Trials Centre, London, UK., Salgado R; Department of Pathology, ZAS Hospitals, Antwerp, Belgium.; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Bridge CP; MGH & BWH Center for Clinical Data Science, Boston, MA, USA., Christiani DC; Department of Medicine, Massachusetts General Hospital/Harvard Medicine School, and Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Mak RH; Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Bay C; Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA., Rosenthal M; Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA., Sattar N; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Welsh P; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Liu Y; Department of Genetics, Harvard Medical School, Boston, USA.; Howard Hughes Medical Institute, Harvard Medical School, Boston, USA., Perrimon N; Department of Genetics, Harvard Medical School, Boston, USA.; Howard Hughes Medical Institute, Harvard Medical School, Boston, USA., Popuri K; Department of Computer Science, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Burnaby, Canada., Beg MF; School of Engineering Science, Simon Fraser University, Burnaby, British Colombia, Canada., McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Hackshaw A; Cancer Research UK & UCL Cancer Trials Centre, London, UK., Breen DM; Internal Medicine Research Unit, Pfizer, Cambridge, MA, USA., O'Rahilly S; Wellcome Trust-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Birkbak NJ; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.; Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark., Aerts HJWL; Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, The Netherlands., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.; Department of Oncology, University College London Hospitals, London, UK. m.jamal-hanjani@ucl.ac.uk., Swanton C; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.swanton@crick.ac.uk.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Charles.swanton@crick.ac.uk.; Department of Oncology, University College London Hospitals, London, UK. Charles.swanton@crick.ac.uk. |
| Corporate Authors: | TRACERx Consortium |
| Source: | Nature medicine [Nat Med] 2023 Apr; Vol. 29 (4), pp. 846-858. Date of Electronic Publication: 2023 Apr 12. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
